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Impaired Endothelial Function and Microvascular
Asymmetrical Dimethylarginine in Angiotensin
II–Infused Rats
Effects of Tempol
Dan Wang, Zaiming Luo, Xiaoyan Wang, Pedro A. Jose, John R. Falck, William J. Welch,
Shakil Aslam, Tom Teerlink, Christopher S. Wilcox
Abstract—Angiotensin (Ang) II causes endothelial dysfunction, which is associated with cardiovascular risk. We
investigated the hypothesis that Ang II increases microvascular reactive oxygen species and asymmetrical dimethyl-
arginine and switches endothelial function from vasodilator to vasoconstrictor pathways. Acetylcholine-induced
endothelium-dependent responses of mesenteric resistance arterioles were assessed in a myograph and vascular NO and
reactive oxygen species by fluorescent probes in groups (n6) of male rats infused for 14 days with Ang II (200 ng/kg
per minute) or given a sham infusion. Additional groups of Ang or sham-infused rats were given oral Tempol
(2 mmol  L1). Ang II infusion increased mean blood pressure (1195 versus 897 mm Hg; P0.005) and plasma
malondialdehyde (0.570.02 versus 0.370.05 mol  L1; P0.035) and decreased maximal endothelium-dependent
relaxation (185% versus 546%; P0.005) and hyperpolarizing (193% versus 293%; P0.05) responses and NO
activity (0.90.1 versus 1.60.2 U; P0.01) yet enhanced endothelium-dependent contraction responses (235%
versus 55%; P0.05) and reactive oxygen species production (0.820.05 versus 0.150.03 U; P0.01). Ang II
decreased the expression of dimethylarginine dimethylaminohydrolase 2 and increased asymmetrical dimethylarginine
in vessels (45050 versus 26035 pmol/mg of protein; P0.01) but not plasma. Tempol prevented any significant
changes with Ang II. In conclusion, Ang redirected endothelial responses from relaxation to contraction, reduced
vascular NO, and increased asymmetrical dimethylarginine. These effects were dependent on reactive oxygen species
and could, therefore, be targeted with effective antioxidant therapy. (Hypertension. 2010;56:950-955.)
Key Words: reactive oxygen species  NO  hypertension  endothelial dysfunction
 dimethylarginine dimethylaminohydrolase
Normal vessels display endothelium-dependent relaxationresponses to acetylcholine (Ach). The endothelium-
dependent relaxation factor (EDRF) is mediated by endothe-
lial NO synthase (NOS). The mediators of the endothelium-
dependent hyperpolarizing factor (EDHF) vary by species
and vascular bed but can include hydrogen peroxide (H2O2),1
epoxyeicosatrienoic acids (EETs),2 and electromechanical
coupling.3 These cause activation of calcium-dependent po-
tassium channels on vascular smooth muscle cells (VSMCs)
that can be blocked by a combination of apamin and charyb-
dotoxin.2 Some vessels also display a cyclooxygenase
(COX)-dependent relaxation response attributable to prosta-
cyclin, although this was not apparent in rat afferent arte-
rioles.2 An endothelium-dependent contracting factor (EDCF)
occurs in models with increased reactive oxygen species
(ROS). The EDCF in renal afferent arterioles from rabbits
infused with angiotensin (Ang) II entailed a vasoconstrictor
prostaglandin generated by COX that activated thromboxane
prostanoid receptors (TP-Rs) on VSMCs.4
Ang II generates ROS in blood vessels that can bioinacti-
vate NO.4 However, NOS-dependent EDRF responses of
resistance arterioles are not consistently reduced4,5 by Ang
infusion. Moreover, ROS can generate an EDCF.4,6 However,
it is not clear whether prolonged inhibition of ROS can
prevent the defects in endothelium-dependent relaxations and
prevent the EDCF responses of resistance vessels from
animals infused with Ang II.
Increasing evidence suggests that an endogenous inhibitor
of NOS, asymmetrical dimethylarginine (ADMA), and its
metabolism by dimethylarginine dimethylaminohydrolase
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(DDAH)7 may regulate vascular NO. Ang II infusion can
increase circulating levels of ADMA.8,9 However, it is un-
clear whether increased ADMA levels in plasma or tissues
can be prevented by an effective antioxidant. We reported
recently that culture of VSMCs with Ang II increased
cellular, but not medium, levels of ADMA.10 To resolve these
issues, we assessed the 3 major endothelium-dependent
pathways and related these responses to vascular NO and
ROS activities and plasma and tissue ADMA concentrations
in mesenteric resistance arteries in rats during a slow pressor
infusion of Ang II. Other groups of sham and Ang II–infused
rats received the antioxidant drug Tempol throughout.11
These experiments were designed to test the hypothesis
that ROS, generated in microvascular resistance vessels
during prolonged Ang II–induced hypertension, impairs
EDRF, EDHF, and NO activity and increases microvascular
ADMA and EDCF. We selected Tempol, which is a redox-
cycling nitroxide, to reduce ROS and enhance vascular NO.11
These experiments are significant because restoration of
endothelial function and NO and abrogation of EDCF, ROS,
and ADMA would reverse some of the earliest manifestations
of hypertension and vascular disease.12
Methods
Male Sprague-Dawley rats (200 to 220 g; Taconics Laboratory) were
maintained on tap water and standard chow (Na 0.4 g  100 g1)
under constant humidity and temperature and 12-hour light-dark
cycles. The protocols were approved by Georgetown University
Institutional Animal Care and Use Committee. Details of methods
appear in the online Data Supplement (please see
http://hyper.ahajournals.org).
Animal Model
Three sets each of 4 groups of Sprague-Dawley rats were prepared
(6 per group were used). Rats were anesthetized with sodium
pentobarbital (50 mg  kg1) for subcutaneous insertion of a sham
minipump (sham) or an osmotic minipump (model 202, Alzato) at
the dorsum of the neck. Group 1 had a sham infusion. Group 2
received Ang II (Peninsula Laboratory) at 200 ng  kg1  min1 for
14 days. Group 3 received a sham minipump and oral Tempol
(2 mmol  L1 of water). Group 4 received an Ang II minipump and
Tempol. On the experimental day, rats were anesthetized with
inhaled isoflurane (3% balance with oxygen). The carotid artery was
cannulated for measurement of mean arterial pressure (model DPM-
1B, Biotek). Blood was withdrawn, and the plasma was stored at
80°C. Thereafter, rats were euthanized by exsanguination, the
abdomen was opened, and mesenteric arteries were isolated and
studied in a myograph or snap frozen and stored at 80°C for
analysis of ADMA or protein.
EDRF/NO, EDHF, and EDCF Responses of
Mesenteric Resistance Arterioles
The mesenteric vessels were isolated, mounted in a Mulvany-
Halpern myograft (JP Trading, Science Park), studied as described in
detail previously,13 described in the online Data Supplement, and
summarized in Figure S1 (see online Data Supplement).
Fluorescence Detection of Ach-Induced NO and
ROS in Mesenteric Resistance Arterioles
These followed methods13 described in details in the online Data
Supplement.
Protein Expression Studies
The protein expression in lysates of isolated mesenteric resistance
arterioles was studied as described previously.13
Plasma Malondialdehyde
Plasma malondialdehyde was measured by high-performance capil-
lary electrophoresis-micellar electrokinetic chromatography (see the
online Data Supplement).
L-Arginine, Asymmetrical, and Symmetrical
Dimethylarginine Concentrations in Plasma
and Tissue
For details, see the online Data Supplement.
Statistics
Values are expressed as meanSEM. The concentration-response
curves to Ach were analyzed using nonlinear regression of sigmoidal
concentration-response curves (GraphPad Prism), which were used
to calculate the EC50. Other values were analyzed by ANOVA
followed by a post hoc test for multiple comparisons (GraphPad
Prism). A value of P0.05 was considered statistically significant.
Results
Mean arterial pressure under anesthesia and plasma malondial-
dehyde were increased by Ang II, but this was prevented in rats
receiving Tempol. There were no changes in plasma arginine,
ADMA, or symmetrical dimethylarginine (SDMA; Table 1).
Figure S1 depicts how endothelium-dependent responses
were assessed (see Figure S1). Responses to Ach are shown
in the Figure and EC50 and maximal values in Table 2.
Compared with sham-infused rats, those infused with Ang II
had a 57% reduction in maximal relaxation with Ach and a
67% reduction in EDRF but a more modest 34% reduction in
EDRF. Ang II enhanced EDCF responses by 4-fold. Ang II
infusion also reduced the sensitivity of the Ach and EDRF
responses but increased the sensitivity of the EDCF responses
and did not change the sensitivity of EDHF responses. There
were no significant effects of Ang II infusion on these
responses in rats administered Tempol (Table 2).
Further data for mesenteric resistance arterioles are shown
in Table 3. Ach-induced DAFFM (4-amino-5-methylamino-
2,7-difluorescein) fluorescence was reduced by 41% in
vessels from Ang-infused rats, whereas Ach-induced Tempo-
9AC-ROS fluorescence was increased 5-fold (Table 3). Both
of these changes were prevented in rats given Tempol. Tissue
concentrations of L-arginine and SDMA in mesenteric vessels
were unaffected by Ang II infusion, but ADMA was in-
creased significantly by 73%. This was prevented by Tempol,
which led to a significant increase in tissue L-arginine in rats
Table 1. Effects of Ang II Infusion Alone or With Tempol on
Mean Arterial Pressure and Plasma Malondialdehyde, L-Arginine,
ADMA, and SDMA
Variable Sham Ang II Tempol
Tempol
Ang II
MAP, mm Hg 897 1195† 90.03 98.26
Malondialdehyde,
mol  L1
0.370.05 0.570.02* 0.460.05 0.450.05
L-Arginine,
mol  L1
17313 17955 13748 14166
ADMA, nmol  L1 51046 594127 61046 70020
SDMA, nmol  L1 28030 30931 30012 3009
Data show meanSEM values (n6 per group).
*Effect of Ang II is P0.05.
†Effect of Ang II is P0.005.
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infused with Ang II. The expression of DDAH-2 protein was
reduced by Ang II infusion but was prevented in rats given
Tempol.
We evaluated whether a reduced response to NO, H2O2, or
EETs could account for the reduced EDRF or EDHF responses
of vessels from Ang-infused rats. The maximal relaxation to the
NO donor, sodium nitroprusside, in vessels from sham-infused
rats (104 M; 978%) was not significantly different (946%)
in vessels from Ang II–infused rats. H2O2 elicited a modest
relaxation of 93% at 105 mol  L1 and a marked relaxation
at 104 mol  L1. However, these responses were similar in
vessels from sham- and Ang-infused rats (Figure S2A). EETs
did not elicit a significant relaxation even at 105 mol  L1
(Figure S2B). Therefore, differences in responsiveness to NO,
H2O2, or EETs could not explain the reduced relaxation re-
sponses from Ang-infused rats.
To assess the role of vasodilator prostaglandins in EDRF
responses, vessels from sham-infused rats were incubated
with 5105 mol  L1 of indomethacin (to block COX-1
and -2). Relaxation responses to 104 M Ach after vehicle
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Figure. MeanSEM values for relaxation responses to Ach in norepinephrine-preconstricted mesenteric arterioles (A) and calculated
EDRF (B), EDHF (C), and EDCF responses in vessels under spontaneous tone (D). Comparing sham- and Ang-infused responses:
*P0.05 and **P0.01. There were no significant differences between sham- and Ang-infused responses in rats given Tempol. B indi-
cates before.
Table 2. Maximal Relaxation Responses and EC50 Values of Vessels to Ach of Mesenteric Arteries From
Vehicle, Ang II, Tempol, and Tempol With Ang II Infusion Rats
Response Maximum, % Maximum, % P Log EC50, mol/L Log EC50, mol/L P
Ach 83.97.9* 36.07.0‡ 0.01 6.170.06* 5.470.04‡ 0.005
EDRF 54.44.6* 18.04.7‡ 0.01 6.550.06* 5.780.05‡ 0.005
EDHF 29.42.7* 18.72.7‡ 0.05 5.180.07* 5.460.16‡ NS
EDCF 5.24.6* 23.05.6‡ 0.05 4.110.35* 4.490.03‡ 0.005
Ach 88.97.9† 69.98.9§ NS 6.210.05† 6.160.08§ NS
EDRF 53.45.7† 41.44.7§ NS 6.760.09† 6.670.01§ NS
EDHF 35.43.7† 27.44.7§ NS 5.380.15† 5.150.14§ NS
EDCF 5.16.2† 10.44.6§ NS 4.160.13† 4.440.07§ NS
Data were obtained from experiments described in Figure 1. NS indicates not significant.
*Data are for vehicle.
†Data are for Tempol.
‡Data are for Ang II.
§Data are for Tempol-Ang II.
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(848%) were unchanged after inhibition of COX with
5105 mol  L1 of indomethacin (796%) but were abol-
ished by endothelium removal (13%). Therefore, indometh-
acin was not used in subsequent relaxation studies.
The mediation of EDHF was studied in vessels from
sham-infused rats with the use of specific inhibitors (Table 4).
EDHF response to 104 M Ach with vehicle was 293%.
This was not significantly blunted by catalase to metabolize
H2O2 or by 14,15-epoxyeicosa-5-(Z)-enoic acid to block
EETs14 in concentrations shown to be effective in isolated
vessels2,15 but was abolished by endothelium removal. Thus,
the EDHF responses depended on the endothelium but were
not mediated significantly by H2O2 or EETs.
The EDCF response of vessels from Ang-infused rats
(Table 5) was not reduced significantly by incubation with
parecoxib to block COX-2 or with OKY-046 to block
thromboxane synthase. However, the response was inhibited
similarly by SC-560 to block COX-1 or SQ-29 548 to block
TP-Rs and was abolished by endothelium removal. These
drug concentrations were fully effective in isolated vessels.4
Thus, EDCF responses depended on the endothelium and
COX-1 products that activated TP-Rs.
Concentrations of L-arginine, ADMA, and SDMA in homog-
enates of aorta, kidney, and liver are shown in Table S1. Tissue
levels of L-arginine and SDMA were unaffected by Ang II
infusion, but levels of ADMA in all 3 of the tissues were
increased. These effects were prevented in rats given Tempol.
Discussion
The main new findings are that a prolonged slow pressor
infusion of Ang II into rats changed endothelial function of
mesenteric resistance vessels by diminishing vasodilator and
increasing vasoconstrictor pathways. This was accompanied by
a reduced endothelial release of microvascular NO and increased
ROS and ADMA. Ang infusion downregulated the vascular
expression of DDAH-2. These effects of Ang II were prevented
by 2 weeks of oral Tempol administration. Plasma ADMA did
not predict vascular, renal, or hepatic tissue levels of ADMA.
We confirmed previous findings that oral Tempol prevented
the increased blood pressure with a slow pressor infusion of Ang
II.11,16 Vascular ROS with Ang II are derived from NADPH
oxidase activity17 and a reduction in extracellular superoxide
dismutase expression.18 Tempol prevented superoxide anion
generation by Ang II in VSMCs19 and inhibited lipid peroxida-
tion and microvascular ROS in response to Ang II in the present
study. We selected a slow pressor rate of Ang II infusion in this
study because high rates of Ang II infusion caused renal damage
that reduced DDAH activity.8
A reduction in EDRF in microvessels of rabbits infused with
Ang II was improved by bath addition of Tempol.20 A reduced
EDRF has been related to bioinactivation of NO by ROS.11 This
is consistent with our findings that Tempol administration
prevented the reduction in microvascular EDRF and NO and the
increase in ROS in rats infused with Ang II.
The maximal EDHF response was also reduced by prolonged
Ang II infusion, but the effect was smaller than on EDRF, and
the EC50 response was not changed. Mediation of EDHF varies
Table 3. Effects of Ang II Infusion Alone or During Tempol Administration on Mesenteric
Resistance Arterioles
Variable Sham Ang II Tempol TempolAng II
NO activity with Ach, F/Fo DAF 1.60.2 1.00.1‡ 1.70.2 1.30.1
ROS activity with Ach, F/Fo tempo 9AC 0.150.03 0.820.05‡ 0.220.05 0.420.11
L-Arginine, nmol  mg of protein1 7125 9523 334 578*
ADMA, pmol  mg protein1 26035 45050† 22836 31236
SDMA, pmol  mg protein1 8050 12776 569 10328
DDAH-2 protein, relative to -actin 1.40.2 0.70.1‡ 1.20.3 1.10.2
Data show meanSEM values (n6 per group) for mesenteric resistance arterioles.
*Effect of Ang II is P0.05.
†Effect of Ang II is P0.01.
‡Effect of Ang II is P0.005.
F/Fo indicates fluorescence relative to basal; DAF, 4-amino-5-methylamino-2,7-difluorofluorescein.
Table 4. Maximal Endothelium-Dependent Hyperpolarization
Responses in Mesenteric Resistance Arterioles From
Sham-Infused Rats
Added to the Bath Relaxation, % P vs Vehicle
Vehicle 293
Catalase, 125 U  mL1 266 NS
14,15-epoxyeicosa-5-(Z)-enoic acid, 105 M 325 NS
Endothelium removal 15 P0.005
Data show meanSEM values (n6 per group). All of the vessels were
preconstricted with 105 mol  L1 of norepinephrine, pretreated with 104
mol  L1 of L-nitroarginine to inhibit NOS and relaxed with 104 mol  L1 of
Ach. NS indicates not significant.
Table 5. Maximum Endothelium-Dependent Contraction Factor
Responses in Mesenteric Resistance Arterioles From Ang
II–Infused Rats
Added to Bath Contraction, % P vs Vehicle
Vehicle 235
SC-560, 107 M 75 P0.005
Parecoxib, 105 M 194 NS
OKY-046 NA, 105 M 133 NS
SQ-29,584, 105 M 64 P0.005
Endothelium removal 14 P0.005
Data show meanSEM values (n6 per group). Vessels were studied under
spontaneous tone. They were pretreated with 104 mol  L1 of
L-nitroarginine, 106 mol  L1 of apamin and 105 mol  L1 of charybdotoxin
to block relaxation responses and constricted with 104 mol  L1 of Ach. NS
indicates not significant.
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by vessel and species21 but can include H2O21 and EETs.2
However, the impaired EDHF responses in this study in mesen-
teric arterioles of rats were independent of H2O2 or EET
generation or action. Thus, neither H2O2 nor EETs caused
significant vasorelaxation except at very high H2O2 concentra-
tions, and the addition of catalase to metabolize H2O2 or the EET
antagonist, 14,15-epoxyeicosa-5-(Z)-enoic acid, to the bath did
not alter EDHF responses. The mediator of EDHF was not
identified in this study.
EDHF is upregulated in blood vessels of endothelial NOS
knockout mice.22 We confirm that Ang II–infused rats have
impaired EDRF responses in mesenteric arterioles.23 Kang et al5
reported that Ang II reduced the sensitivity of mesenteric vessels
to Ach, as in the present study, but reduced the maximal
response only after blockade of NOS. They proposed that NOS
was upregulated in Ang II–infused rats to compensate for a
defect in K-channel–mediated relaxation. However, in our
study, the maximal EDRF response and the Ach-induced NO
activity were reduced in vessels from Ang II–infused rats. The
difference may relate to the lower rate of Ang II infusion.
An endothelium-dependent contraction is apparent in many
models of hypertension.4,24 EDCF responses entailed an
endothelial COX-dependent production of a factor under the
influence of ROS6 that activates TP-Rs on VSMCs.4 The
contractile responses of vessels from Ang II–infused rats in
the present study were prevented by blockade of COX-1,
TP-Rs, or endothelium removal, but blockade of TxA2
(thromboxane A2) synthase had no significant effect. The
present study did not identify the COX-1 product responsible,
but prostaglandin endoperoxides have been implicated. The
vascular signaling of Ang II contractile response via TP-Rs in
this study may underlie the finding that TP-R knockout mice
have an impaired pressor and renal vasoconstrictor response
to infused Ang II.25
The kidney26 and the liver27 clear plasma ADMA, and the
liver clears L-arginine. Avid uptake by these organs may account
for the many-fold higher arginine concentrations in the liver and
ADMA concentrations in the kidney, relative to the other organs
sampled. DDAH-2 is the principal isoform expressed in the rat
mesenteric resistance arterioles13 and DDAH-1 in the renal
proximal tubules.28 The downregulation by Ang II of DDAH-2
in cultured endothelial cells29 and in mesenteric resistance
arterioles in this study and of DDAH-1 in the kidney cortex in a
previous study28 could, therefore, have reduced the metabolism
of ADMA in these organs and contributed to the increased tissue
levels of ADMA. Indeed, Tempol prevented the Ang-induced
reduction in DDAH-2 expression in the mesenteric vessels,
which could have contributed to the prevention of an Ang
II–induced increase in vascular ADMA in Ang-infused rats
receiving Tempol. DDAH activity was not assessed in these
studies. However, Tain and Baylis30 reported that directly
increasing ROS in the kidney cortex decreased DDAH activity.
Because Tempol prevented the Ang II–induced increased
plasma malondialdehyde and vascular ROS activity, this relates
the decreased tissue DDAH-2 expression and increased tissue
ADMA to oxidative stress. However, tissue ADMA is also
increased by upregulation of protein arginine methyltransferases
and by downregulation of cationic amino acid transporters,
which could have contributed to the increased tissue ADMA in
this study.7 We reported recently that incubation of VSMCs with
Ang II increased NADPH oxidase and reduced DDAH and
cationic amino acid transporter activity and increased cellular,
but not medium, levels of ADMA.10 The increase in cellular
ADMA was prevented by Tempol or blockade of Ang type 1
receptors. Further studies in VSMCs transfected with p22phox to
increase NADPH oxidase directly demonstrated reduced
DDAH-1 and -2 expression and activity, increased protein
arginine methyltransferase 3 expression and activity, decreased
cationic amino acid transporter 2A expression and activity, and
increased cellular ADMA concentrations. Thus, ROS can direct
cellular metabolic pathways to increase cellular ADMA concen-
trations, but a reduction in cationic amino acid transporter
activity may restrain ADMA export and limit accumulation of
ADMA in the extracellular fluid or plasma.
The 50% reduction in DDAH-2 expression in mesenteric
vessels with Ang II in this study was similar to that produced by
in vivo gene silencing,13 which impaired EDRF responses and
NO bioactivity in mesenteric arterioles substantially. Moreover,
Torondel et al31 reported that overexpression of DDAH-1 or -2
in vascular endothelial cells reduced ADMA concentrations,
enhanced in vitro vascular NO production, and conferred resis-
tance to administration of ADMA in DDAH heterozygote mice.
The 70% increase in ADMA and 33% reduction in the argin-
ine:ADMA ratio in mesenteric vessels of Ang-infused rats
should contribute to the reduced EDRF responses, because this
would reduce the substrate:inhibitor ratio for NOS. Ang II
increased the mesenteric vascular arginine levels in rats given
Tempol, which also could have contributed to improved EDRF
responses in Tempol-treated rats, but the reason for this was
unclear. Moreover, the increase in superoxide in the blood
vessels during Ang II infusion should have enhanced NO
bioinactivation.11 The finding that the Ang II-induced functional
defects, reduced NO and DDAH-2 expressions, and increased
tissue levels of ADMA and ROS were all prevented by Tempol
implies that an increase in ROS was an upstream event that
impaired endothelial responses by coordinating these pathways
for endothelial dysfunction.
Perspectives
Infusions of Ang II have variable effects on plasma ADMA.
Thus, prolonged Ang II infusions into mice doubled plasma
ADMA in one study,9 whereas in others Ang II did not
change plasma ADMA,8,32 as in the present study, except at
high rates of Ang II infusion that caused renal damage and
reduced renal DDAH expression.8 We find that tissue ADMA
can increase during a slow pressor Ang II infusion despite
unchanged plasma levels.
Endothelial dysfunction or plasma markers of ROS11 or
ADMA33 predict future cardiovascular events or death in
high-risk patients. The present study shows that tissue
ADMA may not always be reflected by plasma levels but that
plasma malondialdehyde was a valid predictor of vascular
ROS. A recent review concluded that the mechanisms that
regulate the balances between NO and EDCF and the pro-
cesses that transform the endothelium from a protective organ
to a source of vasoconstriction and proaggregatory and
promitogenic responses in human hypertension are important
but remain to be determined.24 The present findings that
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Tempol given to Ang II–infused rats prevented the defective
endothelial relaxation responses and NO bioactivity and the
enhanced ROS, endothelial contractions, and ADMA suggest
that vascular ROS is an important component of this trans-
formation of endothelial function. Thus, maneuvers to reduce
ROS could have therapeutic potential.11
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Methods 
 
EDRF/NO, EDHF and EDCF responses of mesenteric resistance arterioles:  After 
equilibration, the vessels were preconstricted with 10-5 mol · l-1 norepinephrine and relaxed with 
acetylcholine (Ach: 10-8 to 10-4 mol · l-1). Thereafter, preconstricted vessels were relaxed with 
the endothelium-independent agent, sodium nitroprusside (10-8 to 10-3 mol · l-1). The EDRF/NO 
response was taken as the relaxation induced by 10-4 mol · l-1 Ach (maximally effective dose) in 
physiological salt solution (vehicle) minus the same response in the presence of 10-4 mol · l-1 NG-
nitro-l-arginine (L-NA) to inhibit nitric oxide synthase.  The EDHF response was taken as the 
inhibition of relaxation by 10-4 mol · l-1 Ach and blockade of calcium-activated potassium 
channels with 10-6 mol · l-1 apamin plus 10-5 mol · l-1 charybdotoxin in the presence of 10-4 mol · 
l-1 L-NA to inhibit EDRF/NO. This combination reduced relaxation by 10-4 mol · l-1 Ach to 
2±6% which was similar to the removal of the endothelium. The EDCF response was calculated 
as the percentage of a standard contraction with norepinephrine (10-5 mol · l-1) and KCl (40 
mmol · l-1) (NAK), which was established at the beginning of the study.  The EDCF responses 
were undertaken without preconstriction in vessels incubated with L-NA, apamin and 
charybdotoxin to block vasodilator pathways during addition of Ach (10-8 to 10-4 mol · l-1) to the 
bath. Preliminary studies in each series established that endothelial denudation abolished Ach-
induced relaxation and contraction. Other preliminary studies detected no effect of blockade of 
COX with 5x10-5 mol · l-1 indomethacin on Ach-induced relaxation.  
 
Mediation of EDHF and EDCF: Further studies investigated the mediation of EDHF 
responses. To assess whether differences in response to H2O2 could account for changes in 
EDRF, preconstricted vessels from sham- and Ang II-infused rats were relaxed with graded 
concentrations of H2O2 (10-7 to 10-4 mol · l-1). EDHF responses of other vessels from sham rats 
were repeated in the presence of pegylated (PEG) catalase (125 units · ml-1).  To assess the role 
of EETs, preconstricted vessels from sham and Ang II-infused rats were relaxed with (Z)-15-
(pentyloxy)pentadec-5-enoic acid (JQ-II-30-20, a stable EET analog) (10-8 to 10-5 mol · l-1). 
Other vessels were studied after bath addition of 14,15-epoxyeicosa-5(Z)-enoic acid (EEZE; 10-5 
mol · l-1) to block EETs and the EDHF response repeated 1. 
To assess the role of COX products in EDCF response, vessels from Ang II-infused rats 
were incubated with SC-560 (10-7 mol · l-1) or N-{[4-(5-methyl-3-phenylisoxazol 4-yl)phenyl] 
sulfonyl}propanamide (parecoxib, 10-6 mol · l-1) to block COX-1 or -2 2 or with [1S-
[1α,2α(Z),3α,4α]]-7-[3-[[2-[(phenylamino)carbonyl]hydrazino]methyl]-7-oxabicyclo[2.2.1]hept-
2-yl]-5-heptenoic acid (SQ-29,548, 10-5 mol · l-1; Bristol Myers Squib, Inc, New Jersey) to block 
TP-Rs or with ozagrel hydrochloride hydrate (OKY-046, 10-5 mol · l-1) to block thromboxane A2 
synthase 2 for 30 minutes prior to testing. These concentrations produced maximal effects on 
isolated vessels 2. 
 
Fluorescence detection of acetylcholine–induced nitric oxide and ROS in mesenteric 
resistance arterioles: To assess NO activity, vessels were loaded with 4-amino-5-
methoxyamino-2',7'-difluorofluorescein diacetate (DAFFM-DA; Invitrogen, Carlsbad, CA) for 
30 min, and rinsed three times 3,4. DAFFM-DA is taken into cells, trapped by de-esterification 
and covalently modified by NO to a fluorescent triazolo-fluorescin analog 3. Thirty minutes after 
loading with excitation at 495 nm, and emissions isolated at 515 nm, the vessels were 
precontracted with 10-5 mol · l-1 norepinephrine and relaxed with 10-4 mol · l-1 Ach.  The change 
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in fluorescence (ΔF1/F0) was detected by an inverted microscope (Olympus 1x71, Tokyo, Japan) 
equipped with a 20x objective and an emission photon detection fluorescence system (Ratio 
Master, Photon Technology International; Lawrenceville, NY) and measured with a photon-
counting assembly (D104B; Photon Technology International). Responses were confirmed 
(Cayman Chemicals, Ann Arber, MI) by showing that 90% of the response to Ach was prevented 
by 10-5 mol · l-1 L-NA without affecting the response to the NO donor compound 5x10-5 mol · l-1 
2–(N,N– diethylamino) diazenolate-2-oxide sodium salt (NONOate; data not shown). 
To assess ROS, the vessels were preloaded with 4-((9-acridinecarbonyl)amino)-2,2,6,6-
tetramethylpiperidin- 1-oxyl free radical (TEMPO-9-AC; 10-5 mol · l-1) 5.  The vessels were 
prepared as for EDCF studies and stimulated with 10-4 mol · l-1 Ach with excitation at 360 nm 
and emission at 460 nm.  Preliminary studies in vessels pretreated with PEG superoxide 
dismutase (125 units · ml-1) prevented 92% of the fluorescent response to Ach in vessels from 
Ang II-infused rats.   
 
Plasma malondialdehyde: Plasma ultrafiltrate was injected (127 nanoliter under 1 psi for 
10 seconds) into an uncoated fused silica capillary (75 micron ID, length to detector 40 cms, total 
length 50.2 cms) on a Beckman Coulter MDQ system (Fullerton, CA). The background 
electrolyte solution contained borate 50 mM, spermine 1 mM, and tetradecyltrimethylammonium 
bromide 2 mM at a pH of 9.7. UV detection was carried out at 260 nm. The MDA peak 
(migration time 5.2 minutes) was identified by spiking the samples. The separation was carried 
out at -12kV and 25°C. Intra- and inter-assay coefficients of variation in plasma were 2.1% and 
4.3%, respectively.  
L-arginine, asymmetric - and symmetric - dimethylarginine concentrations in plasma 
and tissue:  Separate groups of rats (n=6 per group) were used for these studies.  Under 
pentobarbital anesthesia (50 mg · kg-1 ip), a carotid artery was cannulated, 1 ml of blood 
removed, and the plasma separated with care to avoid hemolysis.  Mesenteric vessels, the aorta, 
the renal cortex, and the liver were removed, washed rapidly in isotonic saline, snap-frozen in 
liquid nitrogen and stored at -80ºC prior to analysis for L-arginine, ADMA and symmetric 
dimethylarginine (SDMA) concentrations 6,7.  The isolated aortas, mesenteric vessels, liver and 
renal cortex from Sprague-Dawley rats were washed three times with ice-cold PBS, transferred 
to a Lysing Matrix D tube (MP Biomedicals, Solon, OH) containing 1:10 volume of 0.6 mol/L 
ice-cold perchloric acid (Sigma, St. Louis, MO) and homogenized in a FastPrep (Thermo 
Electron Corporation, Waltham, MA). After homogenization, 20µl of each sample of tissue 
homogente was placed in a tube for protein measurement. The remainder was centrifuged for 10 
minutes at 2,000 g at 4ºC, the clear supernatant collected and stored at -80 ºC.  This avoided 
artefactual increases (by proteolysis) or decreases (by DDAH) of ADMA. ADMA , SDMA and 
arginine are stable in the clear supernatant, which was neutralized shortly before HPLC 
analysis.  Concentrations of L-arginine, ADMA and SDMA in plasma and supernatant were 
measured by HPLC with fluorescence detection as previously described 6 using modified 
chromatographic separation conditions 7. Supernatants obtained after deproteinization of tissue 
homogenate with perchloric acid were neutralized with two volumes of 0.5 M Na2HPO4 to one 
volume of the supernatant. Supernatant and plasma were spiked with monomethylarginine as an 
internal standard and purified by solid-phase extraction on polymeric cation-exchange columns. 
Thereafter, the samples were dried with nitrogen, and derivatized with ortho-phthaldialdehyde 
reagent containing 3-mercaptopropionic acid. Analytes were separated by isocratic reversed-
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phase HPLC with fluorescence detection. A human plasma pool was analyzed in all analytical 
series as a quality control. For all analytes the intra- and inter-assay coefficients of variation were 
<1.5% and <3.5%, respectively. Supernatant concentrations were normalized to protein content.  
 
Results  
 
Figure S1 depicts how endothelium-dependent responses were assessed.  Panels A and B 
are from vessels from sham rats, and panel C from Ang II infused rats (which had a robust 
EDCF). The EDRF responses were the differences between acetylcholine-induced relaxations 
alone and during blockade of NOS with 10-4 mol · l-1 L-NA (Panel A).  The EDHF responses 
were the differences between the L-NA pretreated vessel alone and during apamin and 
charybdotoxin (Ap + Ctx; panel B).  The latter almost abolished the relaxation, similar to high 
KCl solution (40 mmol · l-1 KCl).  Contraction responses were obtained in vessels under 
spontaneous tone pretreated with L-NA, Ap and Ctx to prevent confounding effects of relaxation 
responses.  Endothelium removal (Endo-) prevented the relaxation and contraction responses.  
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Supplemental Table 
 
Table S1.  Effects of angiotensin II infusion alone or during tempol administration on L-
arginine, ADMA or SDMA in aorta, kidney and liver homogenates  
 
Condition Aorta Kidney Liver 
 
A. L-arginine (nmol · mg protein-1)  
Sham 21 ± 5 90 ± 5 918 ± 86 
Ang II 19 ± 2 112 ± 10 886 ± 140 
Tempol 18 ± 2 63 ± 15 830 ± 96 
Ang II+Tempol 17 ± 1 71 ± 3 947 ± 101 
 
B. ADMA  (pmol · mg protein-1) 
Sham 69 ± 10 1,330 ± 220 200 ± 32 
Ang II 126 ± 17* 2,360 ± 240† 416 ± 74* 
Tempol 84 ± 8 1,410 ± 375 217 ± 11 
Ang II+Tempol 80 ± 8 1,880 ± 290 300 ± 43 
 
C. SDMA (pmol · mg protein-1) 
Sham 37 ± 6 301 ± 47 159 ± 21 
Ang II 36 ± 6 461 ± 29 118 ± 17 
Tempol 20 ± 5 382 ± 68 43 ± 7 
Ang II+Tempol 
 
14 ± 3 546 ± 65 43 ± 7 
 
Mean ± SEM values (n = 6 per group). Effects of Ang II: *, P<0.05; †, P<0.01. 
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Supplemental Figures 
 
 
 
 
 
 
Figure S1: Mean ± SEM values for endothelium derived relaxing factor (Panel A), endothelium 
derived hyperpolarizing factor (Panel B), both in vessels from normal rats, and endothelium 
derived contracting factor (Panel C) in vessels from angiotensin infused rats. L-NA, L-Nitro 
arginine; Endo-, endothelium removal; Ap, apomin; Ctx, charybdotoxin. 
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Figure S2: Relaxation responses to H2O2 (Figure A) or the stable epoxyeicosatrienoic acid 
derivative, (Z)-15-(pentyloxy)pentadec-5-enoic acid (JQ-II-30-20) (Figure B) comparing results 
in sham-infused rats (open circles) or rats infused with Ang II (solid circles). 
 
 
 
 
 8
 at Vrije on July 11, 2011http://hyper.ahajournals.org/Downloaded from 
